Company

Cancer is a leading global cause of death and emerges from healthy cells transforming into tumor cells due to genetic factors and external influences.

Despite the variety of over 100 diseases it encompasses, current treatments remain limited and often bring unwanted side effects.

We at YGION are committed to creating precision therapies eliminating tumors without harming patients. Recognizing that every patient and tumor is unique, we strive for customized treatments tailored to each patient’s specific condition.

Ygion Team

Our Leadership Team

Founded in 2022 by a group of scientific innovators, YGION has grown into an international, multidisciplinary team dedicated to tackling the challenges of cancer genomics and immunotherapy.

Management

Sophie Zettl

Wolfgang Fischl, PhD

Chief Executive Officer, Co-founder

Sophie Zettl

Georg Casari, PhD

Chief Operating Officer, Co-founder

Sophie Zettl

Sophie Zettl, PhD

Chief Business Officer

Sophie Zettl

Anna-Dorothea Gorki, PhD

Chief Scientific Officer

Advisors

Geert Mudde

Geert Mudde, PhD

Co-Founder, Advisor

Alexander Seitz

Gottfried Himmler, PhD

Co-Founder, Advisor

Gottfried Himmler

Alexander Seitz, MD

Co-Founder, Advisor

Our Partners

Kamosys Logo

 

Generously Supported By

FFG Logo

From complexity to clarity: Unique therapies for unique patients.